Arcus Biosciences is a clinical-stage biotechnology company with a 28% analyst upside and above-average momentum, but its core pipeline is heavily concentrated in a single drug candidate and a single partnership counterparty, revenue is declining 39% year-over-year, and the company is burning cash at 66% of revenue — meaning thesis viability depends almost entirely on pipeline outcomes the data cannot predict.
Thesis pillars
- Pipeline And Counterparty Concentration→Stable
- Revenue Decline Cash Burn→Stable
- High Put Call Ratio Market Skepticism↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026· older than 90 days
Arcus Biosciences, Inc. (RCUS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Below long-term trend.
Arcus Biosciences is a late clinical-stage biopharmaceutical company with four drugs in Phase 3 trials targeting cancers and inflammatory diseases. Revenue comes from collaboration milestones with Gilead Sciences (which holds exclusive commercialization rights outside the U.S.... Read more
Sell if holding. Engine safety override at $19.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — Arcus Biosciences, Inc.
Latest news
- NEWS Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update — fiscal.ai Nov 4, 2026
- NEWS Arcus Biosciences Q3 EPS $(1.00) Misses $(0.90) Estimate, Sales $9.000M Beat $8.305M Estimate — benzinga Nov 4, 2026 negative
- NEWS Arcus Biosciences Scheduled to Report Third Quarter 2026 Financial Results — fiscal.ai Nov 3, 2026
- NEWS Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 — fiscal.ai Nov 2, 2026
- NEWS 12 Health Care Stocks Moving In Monday's Pre-Market Session — benzinga Nov 2, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:49:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinecasdatifan10-K Item 1: 'We currently own all of the commercial rights to casdatifan ... Our first Phase 3 clinical trial, PEAK-1, is evaluating casdatifan'
- HIGHcounterpartyGilead10-K Item 1A: 'We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products.'
- HIGHSupplierWuXi Biologics10-K Item 1: 'WuXi Biologics would be our exclusive manufacturer of zimberelimab drug substance with respect to clinical and commercial supplies'
- HIGHSuppliersingle-source contract manufacturers10-K Item 1: 'we have obtained ... drug product for our investigational products from single-source third-party contract manufacturers'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMCOO Jennifer Jarrett resigned effective March 30, 2026. No disagreement with Company operations, policies, or practices cited. Separation agreement provides advisory services through June 30, 2026 with extended option exercise period. No permanent successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.31: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 5.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $17.96. Score 4.6/10, moderate confidence.
Analyst target: $35.67 (+84.7% upside). Prior stop was $17.96. Stop-loss: $17.96.
Concentration risk — Pipeline: casdatifan; Concentration risk — Counterparty: Gilead; Quality below floor (2.0 < 4.0).
Arcus Biosciences, Inc. trades at a P/E of N/A (forward -6.2). TrendMatrix value score: 5.4/10. Verdict: Sell.
21 analysts rate RCUS, with a consensus score of 4.1/5. 12 analysts publish price targets averaging $41.
What does Arcus Biosciences, Inc. do?Arcus Biosciences is a late clinical-stage biopharmaceutical company with four drugs in Phase 3 trials targeting...
Arcus Biosciences is a late clinical-stage biopharmaceutical company with four drugs in Phase 3 trials targeting cancers and inflammatory diseases. Revenue comes from collaboration milestones with Gilead Sciences (which holds exclusive commercialization rights outside the U.S. for anti-TIGIT, anti-PD-1, and CD73 programs) and Taiho Pharmaceutical. Arcus retains U.S. commercial rights to its lead HIF-2α inhibitor casdatifan, currently in Phase 3 in renal cell carcinoma.